Elite Pharmaceuticals Financial Results
Elite Pharmaceuticals reported financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 10.4% to $40.1 million. The growth was driven by the company's Elite label amphetamine and naltrexone product lines, leading to a 21% increase in operating income to $9.9 million.
- Term
- Q2 2027